VINC
Vincerx Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+0.00%Year over year
Reported trailing growth
- Revenue
- -18.7%
- EBITDA
- +22.9%
- EBIT
- +21.9%
- EPS
- +35.8%
- Free cash flow
- +34.9%
- Operating cash flow
- +34.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +19.8%
- EBIT
- +26.2%
- Net income
- +25.1%
- EPS
- +15.9%
- Free cash flow
- +35.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2025